Madrigal Pharmaceuticals, Inc. MDGL Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $401K in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 414.1% year-over-year, from $78K to $401K.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 3 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -18.5% compound annual growth rate (CAGR), from $37K to $20K.